Article

New COPD Target Could Lead to Innovative Treatments

Author(s):

Using an innovative technique, German researchers highlighted a new pathway they believe could provide updated chronic obstructive pulmonary disease (COPD) treatments.

Using an innovative technique, German researchers highlighted a new pathway they believe could provide updated chronic obstructive pulmonary disease (COPD) treatments.

Published in the European Respiratory Journal, their study used 3D human lung tissue cultures (3D-LTCs) to show how Wnt/β-catenin signalling pathway activation could repair COPD patients’ lung tissues.

The Wnt/β-catenin signalling pathway, one of many pathways tasked with transducing signals for cells that respond to external stimuli, is sparked by a key mediator protein called Wnt. Also relevant to the pathway’s name, Wnt also works with the β-catenin protein during transduction, a press release pointed out.

Researchers were able to see how the pathway was able to heal damaged lung tissues by using 3D with high spatio-temporal resolution, a process which includes quantitative polymerase chain reaction (PCR), Western blotting, enzyme-linked immunosorbent assay (ELISA), immunohistological assessment, and four-dimensional confocal live tissue imaging.

“Previously, studies largely relied on animal models, and cell cultures in the petri dish were limited to two dimensions and individual time points,” Franziska Uhl, a doctoral student at the Comprehensive Pneumology Center of Helmholtz Zentrum München, explained in the statement.

With this new method, the authors claimed they can now gauge how well targeted treatments are working on their COPD patients and could influence how precision medicine is practiced. Moreover, the discovery of the Wnt/β-catenin signalling pathway could spell worthwhile COPD therapies.

“We hope in this way to develop long-term treatments that induce lung tissue repair in the patients,” lead author Melanie Königshoff explained.

Related Videos
How to Manage Aspirin-Exacerbated Respiratory Disease
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
MeiLan Han, MD: Discussing Updates on Dupilumab, Ensifentrine in 2025 GOLD Report
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
How Artificial Intelligence is Being Used in Lung Imaging, with Rachel Eddy, PhD
Developing Risk Assessment Tools for Viruses in School
Using Microbiomes to Diagnose Ventilator-Associated Pneumonia
What Do Patients Need to Learn About their Hypersensitivity Pneumonitis?
© 2024 MJH Life Sciences

All rights reserved.